Apellis Medical Hub
  • Science
    • PNH
    • Geographic Atrophy
    • ALS
    • C3G / IC -MPGN
    • CAD
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.
  • Menu Menu
  • Science
    • PNH
    • Geographic Atrophy
    • ALS
    • C3G / IC -MPGN
    • CAD
    • HSCT-TMA
    • Pipeline
  • Medical Research
    • Scientific Focus
    • Investigator Initiated Trials
    • Collaborative Research
    • Medical Writing Grants
  • Congress & Manuscripts
    • Congress Presentations
    • Manuscripts
  • Resources
    • Medical Information
    • Early Access & Compassionate Use Program
    • Prescribing Information
  • Search
  • This website is intended only for use by U.S. Healthcare Professionals.

Immune Complex Membranoproliferative Glomerulonephritis (IC-MPGN) and C3 Glomerulopathy (C3G)

IC-MPGN and C3G are rare kidney diseases. In both diseases, an important part of the immune system known as the complement cascade is overactive, which results in the excessive breakdown of a protein called C3.1 These C3 breakdown products become trapped in the kidney, causing inflammation and damage to the organ.1

Although IC-MPGN is a distinct disease from C3G, the underlying cause and progression of the two diseases are remarkably similar.2,3 The signs and symptoms of IC-MPGN and C3G include blood in the urine (hematuria); dark foamy urine due to the presence of protein (proteinuria); edema (swelling), often in the legs, although any part of the body can be affected; high blood pressure; and decreased urine output.4

There are no therapies currently approved for IC-MPGN or C3G, so there is a substantial need for medicines that target the cause of the diseases. IC-MPGN and C3G can lead to kidney failure within five to 10 years of diagnosis in up to 50% of patients, requiring these patients to go on dialysis or get a kidney transplant.5

If you have questions about our clinical trials, please email us at clinicaltrials@apellis.com. Learn more about ongoing, C3G/IC-MPGN Apellis-sponsored clinical trials below.

Medical Resources

Clinical Trials

Valiant: www.clinicaltrials.gov/ct2/show/NCT05067127?term=NCT05067127&draw=2&rank=1
Noble: www.clinicaltrials.gov/ct2/show/NCT04572854?term=pegcetacoplan&cond=c3g&draw=2&rank=1

Study Sites

Valiant: www.thevaliantstudy.com/us/en
Noble: www.thenoblestudy.com/us/en

Congress Presentations

Medical Research

References

  1. Genetics Home Reference. Available at: www.ghr.nlm.nih.gov/condition/c3-glomerulopathy. Accessed November 27, 2019.
  2. Noris M, Donadelli R, Remuzzi G. Autoimmune abnormalities of the alternative complement pathway in membranoproliferative glomerulonephritis and C3 glomerulopathy. Pediatr Nephrol. 2019 Aug;34(8):1311-1323.
  3. Cook HT. Evolving complexity of complement-related diseases: C3 glomerulopathy and atypical haemolytic uremic syndrome. Curr Opin Nephrol Hypertens. 2018 May;27(3):165-170.
  4. Complement 3 Glomerulopathy (C3G). National Kidney Foundation Website. www.kidney.org/atoz/content/complement-3-glomerulopathy-c3g. Accessed November 21, 2019.
  5. C3 glomerulopathy. National Institute of Health, Genetics Home Reference. www.ghr.nlm.nih.gov/condition/c3-glomerulopathy#resources. Accessed Novemer 21, 2019.

Report an Adverse Event or Product complaint

Please call 833-866-3346

Ask a Medical Question

Please click here or call
833-866-3346 (833-TO-MEDINFO)

Connect with an MSL

Set up a meeting with your
Medical Science Liaison

Privacy PolicyTerms and Conditions

©2023 Apellis Pharmaceuticals, Inc. All rights reserved. 08/23 MED-US-CORP-22-00001 v7.0
Scroll to top
You are now leaving ApellisMedicalHub.com

You are about to leave ApellisMedicalHub.com to visit a third-party website. We recommend reviewing the privacy policy and terms & conditions of any site you visit, as Apellis Pharmaceuticals, Inc. is not responsible for their content.

I agree
Landing

Landing

You are entering a website that is technical in nature and was created for scientific exchange with Healthcare Professionals. The content on this website may include scientific information about investigational compounds or indications that are not approved. Apellis does not support, endorse or recommend the unapproved use of any compound, including those discussed on this website.
Are you a Healthcare Professional licensed to practice in the country or region selected above? If you are not a Healthcare Professional, you will be redirected to www.apellis.com(Required)
Enter
Enter
Enter
Enter
Enter

Apellis Medical Affairs

You are entering a website that is technical in nature and was created for scientific exchange with U.S. Healthcare Professionals. The content on this website may include scientific information about investigational compounds or indications that are not approved. Apellis does not support, endorse or recommend the unapproved use of any compound, including those discussed on this website.

Are you a U.S. Healthcare Professional licensed to practice in the United States? 

If you are not a U.S. Healthcare Professional, you will be redirected to www.apellis.com